11 research outputs found

    High-angle-of-attack pneumatic lag and upwash corrections for a hemispherical flow direction sensor

    Get PDF
    As part of the NASA F-14 high angle of attack flight test program, a nose mounted hemispherical flow direction sensor was calibrated against a fuselage mounted movable vane flow angle sensor. Significant discrepancies were found to exist in the angle of attack measurements. A two fold approach taken to resolve these discrepancies during subsonic flight is described. First, the sensing integrity of the isolated hemispherical sensor is established by wind tunnel data extending to an angle of attack of 60 deg. Second, two probable causes for the discrepancies, pneumatic lag and upwash, are examined. Methods of identifying and compensating for lag and upwash are presented. The wind tunnel data verify that the isolated hemispherical sensor is sufficiently accurate for static conditions with angles of attack up to 60 deg and angles of sideslip up to 30 deg. Analysis of flight data for two high angle of attack maneuvers establishes that pneumatic lag and upwash are highly correlated with the discrepancies between the hemispherical and vane type sensor measurements

    Pharmaceuticals and personal care products in the environment: What are the big questions?

    Get PDF
    Background: Over the past 10-15 years, a substantial amount of work has been done by the scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals and personal care products (PPCPs) in the environment. Objective: This review was undertaken to identify key outstanding issues regarding the effects of PPCPs on human and ecological health in order to ensure that future resources will be focused on the most important areas. Data sources: To better understand and manage the risks of PPCPs in the environment, we used the "key question" approach to identify the principle issues that need to be addressed. Initially, questions were solicited from academic, government, and business communities around the world. A list of 101 questions was then discussed at an international expert workshop, and a top-20 list was developed. Following the workshop, workshop attendees ranked the 20 questions by importance. Data synthesis: The top 20 priority questions fell into seven categories: a) prioritization of substances for assessment, b) pathways of exposure, c) bioavailability and uptake, d) effects characterization, e) risk and relative risk, f) antibiotic resistance, and g) risk management. Conclusions: A large body of information is now available on PPCPs in the environment. This exercise prioritized the most critical questions to aid in development of future research programs on the topic.Centro de Investigaciones del Medioambient

    Pharmaceuticals and personal care products in the environment: What are the big questions?

    Get PDF
    Background: Over the past 10-15 years, a substantial amount of work has been done by the scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals and personal care products (PPCPs) in the environment. Objective: This review was undertaken to identify key outstanding issues regarding the effects of PPCPs on human and ecological health in order to ensure that future resources will be focused on the most important areas. Data sources: To better understand and manage the risks of PPCPs in the environment, we used the "key question" approach to identify the principle issues that need to be addressed. Initially, questions were solicited from academic, government, and business communities around the world. A list of 101 questions was then discussed at an international expert workshop, and a top-20 list was developed. Following the workshop, workshop attendees ranked the 20 questions by importance. Data synthesis: The top 20 priority questions fell into seven categories: a) prioritization of substances for assessment, b) pathways of exposure, c) bioavailability and uptake, d) effects characterization, e) risk and relative risk, f) antibiotic resistance, and g) risk management. Conclusions: A large body of information is now available on PPCPs in the environment. This exercise prioritized the most critical questions to aid in development of future research programs on the topic.Fil: Boxall, Alistair B. A.. University of York; Reino UnidoFil: Rudd, Murray A.. University of York; Reino UnidoFil: Brooks, Bryan W.. Baylor University; Estados UnidosFil: Caldwell, Daniel J.. Johnson & Johnson; Estados UnidosFil: Choi, Kyungho. Seoul National University; Corea del SurFil: Hickmann, Silke. Umweltbundesamt; AlemaniaFil: Innes, Elizabeth. Health Canada; CanadáFil: Ostapyk, Kim. Health Canada; CanadáFil: Staveley, Jane P.. Exponent; Estados UnidosFil: Verslycke, Tim. Gradient; Estados UnidosFil: Ankley, Gerald T.. United States Environmental Protection Agency; Estados UnidosFil: Beazley, Karen F.. Dalhousie University Halifax; CanadáFil: Belanger, Scott E.. Procter And Gamble; Estados UnidosFil: Berninger, Jason P.. Baylor University; Estados UnidosFil: Carriquiriborde, Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Química. Centro de Investigaciones del Medio Ambiente; ArgentinaFil: Coors, Anja. Ect Oekotoxikologie Gmbh; AlemaniaFil: DeLeo, Paul C.. American Cleaning Institute; Estados UnidosFil: Dyer, Scott D.. Procter And Gamble; Estados UnidosFil: Ericson, Jon F.. Pfizer Inc.; Estados UnidosFil: Gagné, François. Environment Canada; CanadáFil: Giesy, John P.. University of Saskatchewan; CanadáFil: Gouin, Todd. Unilever; Reino UnidoFil: Hallstrom, Lars. University of Alberta; CanadáFil: Karlsson, Maja V.. University of York; Reino UnidoFil: Joakim Larsson, D.G.. University of Göteborg; AlemaniaFil: Lazorchak, James M.. United States Environmental Protection Agency; Estados UnidosFil: Mastrocco, Frank. Pfizer Inc.; Estados UnidosFil: McLaughlin, Alison. Health Canada; CanadáFil: McMaster, Mark E.. Environment Canada; CanadáFil: Meyerhoff, Roger D.. Eli Lilly And Company; Estados UnidosFil: Moore, Roberta. Health Canada; CanadáFil: Parrott, Joanne L.. Environment Canada; CanadáFil: Snape, Jason R.. AstraZeneca UK Ltd.; Reino UnidoFil: Murray-Smith, Richard. AstraZeneca UK Ltd.; Reino UnidoFil: Servos, Mark R.. University of Waterloo; CanadáFil: Sibley, Paul K.. University of Guelph; CanadáFil: Straub, Jürg Oliver. F. Hoffmann-La Roche Ltd.; SuizaFil: Szabo, Nora D.. University of Ottawa; CanadáFil: Topp, Edward. Agriculture Et Agroalimentaire Canada; CanadáFil: Tetreault, Gerald R.. University of Waterloo; CanadáFil: Trudeau, Vance L.. University of Ottawa; CanadáFil: Van Der Kraak, Glen. University of Guelph; Canad

    The p53 family: Guardians of maternal reproduction

    No full text
    The p53 family of proteins consists of p53, p63 and p73, which are transcription factors that affect both cancer and development. It is now emerging that these proteins also regulate maternal reproduction. Whereas p63 is important for maturation of the egg, p73 ensures normal mitosis in the developing blastocyst. p53 subsequently regulates implantation of the embryo through transcriptional control of leukaemia inhibitory factor. Elucidating the cell biological basis of how these factors regulate female fertility may lead to new approaches to the control of human maternal reproduction
    corecore